Aerovate Therapeutics, Inc. (AVTE) News
Filter AVTE News Items
AVTE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest AVTE News From Around the Web
Below are the latest news stories about AEROVATE THERAPEUTICS INC that investors may wish to consider to help them evaluate AVTE as an investment opportunity.
Jade, another biotech spinout of Paragon, to merge with AerovateThe immune disease drug developer expects to raise $300 million in a private financing set to close before its combination with the struggling Aerovate. |
Aerovate Therapeutics and Jade Biosciences Announce Merger AgreementMerger to create a company focused on advancing Jade Biosciences’ portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025 Approximately $300 million raised to date, including anticipated proceeds from an oversubscribed pre-closing private financing, expected to fund operations t |
Aerovate Therapeutics to Explore Strategic AlternativesWALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of this review process, Aerovate has engaged Wedbush PacG |
Ligand to buy Apeiron; Roche reports another TIGIT setbackAcquiring Apeiron will hand Ligand royalty rights on the neuroblastoma drug Qarziba. Elsewhere, CSL reported the first commercial treatment of patients in Europe with its gene therapy Hemgenix. |
Aerovate slashes workforce after failed Phase IIb trialThe company has announced plans to lay off 39 employees, with most of the workforce cuts expected in coming months. |
The 3 Hottest Stock Downgrades From Last WeekWall Street’s leading analysts have been adjusting their S&P 500 forecasts in recent days. Driven by potential Federal Reserve interest rate cuts, strong performance from large technology companies and solid corporate earnings growth, analysts expect the S&P 500 to consolidate its gains above 5500. According to LSEG data, collective S&P 500 profits are expected to increase by approximately 10.7% from the previous year to $495.7 billion, surpassing the 8% growth seen in the first quarter. Evercor |
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study GoalsAerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients. |
Why 93% Of Aerovate Therapeutics' Value Just Went Up In SmokeAerovate Therapeutics said Monday its experimental blood pressure medicine failed in Phase 2 testing, and the biotech stock plummeted 93%. |
Top Midday DeclinersTop Midday Decliners |
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial HypertensionAV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied dosesWALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial of AV-101, a novel dry powder inhaled formulation of imatinib, |